HK1142128A1 - Methods of prognosis - Google Patents
Methods of prognosisInfo
- Publication number
- HK1142128A1 HK1142128A1 HK10108448.9A HK10108448A HK1142128A1 HK 1142128 A1 HK1142128 A1 HK 1142128A1 HK 10108448 A HK10108448 A HK 10108448A HK 1142128 A1 HK1142128 A1 HK 1142128A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- prognosis
- methods
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2007905761A AU2007905761A0 (en) | 2007-10-22 | Methods of prognosis | |
PCT/AU2008/001554 WO2009052557A1 (en) | 2007-10-22 | 2008-10-22 | Methods of prognosis |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1142128A1 true HK1142128A1 (en) | 2010-11-26 |
Family
ID=40578957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10108448.9A HK1142128A1 (en) | 2007-10-22 | 2010-09-06 | Methods of prognosis |
Country Status (8)
Country | Link |
---|---|
US (4) | US20110039284A1 (ja) |
EP (1) | EP2208072B1 (ja) |
JP (2) | JP5272011B2 (ja) |
CN (1) | CN101861522B (ja) |
CA (1) | CA2701945A1 (ja) |
ES (1) | ES2543985T3 (ja) |
HK (1) | HK1142128A1 (ja) |
WO (1) | WO2009052557A1 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150017671A1 (en) | 2004-04-16 | 2015-01-15 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
EP2350669B9 (en) | 2008-10-31 | 2014-06-11 | St Vincent's Hospital Sydney Limited | Methods of prognosis in chronic kidney disease |
WO2011050407A1 (en) * | 2009-10-28 | 2011-05-05 | St Vincent's Hospital Sydney Limited | Methods of diagnosing and prognosing colonic polyps |
EP2573566A1 (en) * | 2011-09-20 | 2013-03-27 | Atlas Antibodies AB | RBM3 in prostate cancer prognostics |
CA2862516C (en) | 2012-03-27 | 2023-02-14 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
KR101993714B1 (ko) | 2013-01-30 | 2019-06-28 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사 장애를 치료하는데 이용하기 위한 조성물과 방법 |
US11761962B2 (en) | 2014-03-28 | 2023-09-19 | Opko Diagnostics, Llc | Compositions and methods related to diagnosis of prostate cancer |
AP2016009663A0 (en) | 2014-07-30 | 2016-12-31 | Ngm Biopharmaceuticals Inc | Compositions and methods of use for treating metabolic disorders |
TN2017000113A1 (en) | 2014-10-31 | 2018-07-04 | Ngm Biopharmaceuticals Inc | Compositions and methods of use for treating metabolic disorders |
JP2018504595A (ja) * | 2015-01-05 | 2018-02-15 | ユニバーシティ オブ オスロUniversity of Oslo | 前立腺癌マーカー及びその利用 |
MX2017012320A (es) | 2015-03-27 | 2018-01-18 | Opko Diagnostics Llc | Estandares de antigeno prostatico y sus usos. |
JP6829444B2 (ja) * | 2016-02-29 | 2021-02-10 | 公立大学法人横浜市立大学 | 去勢抵抗性前立腺癌を検出する方法及び検出試薬 |
SG11201807279QA (en) | 2016-03-31 | 2018-09-27 | Ngm Biopharmaceuticals Inc | Binding proteins and methods of use thereof |
JP7127422B2 (ja) * | 2017-08-30 | 2022-08-30 | 東ソー株式会社 | 癌を検出する方法及び検出試薬 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994003599A1 (en) * | 1992-08-04 | 1994-02-17 | Sagami Chemical Research Center | HUMAN cDNA AND PROTEIN WHICH SAID cDNA CODES FOR |
US6180602B1 (en) * | 1992-08-04 | 2001-01-30 | Sagami Chemical Research Center | Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent |
US6521227B1 (en) * | 1999-11-18 | 2003-02-18 | Peter L. Hudson | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
US5994102A (en) * | 1994-12-15 | 1999-11-30 | Human Genome Sciences, Inc. | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
JP2001500382A (ja) * | 1996-09-30 | 2001-01-16 | ヒューマン ジノーム サイエンシーズ,インコーポレイテッド | 骨髄前駆体阻害因子―1(mpif―1)、単球コロニー阻害因子(m―cif)、およびマクロファージ阻害因子―4(mip―4)で疾患状態を処置するための治療組成物および方法 |
AU8591198A (en) * | 1997-07-31 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-15 |
US6465181B2 (en) * | 1999-03-25 | 2002-10-15 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
ATE470863T1 (de) * | 2000-04-20 | 2010-06-15 | St Vincents Hosp Sydney | Diagnostischer assay mit makrophagenhemmendem zytokin-1 (mic-1) |
WO2002059373A2 (en) * | 2001-01-23 | 2002-08-01 | Irm, Llc | Genes overexpressed in prostate disorders as diagnostic and therapeutic targets |
WO2002092124A1 (en) * | 2001-05-11 | 2002-11-21 | Wyeth | Methods for diagnosing and treating ischemia and reperfusion injury and compositions thereof |
AU2002335640A1 (en) * | 2001-08-17 | 2003-03-03 | Affymetrix, Inc. | Gleason grade 4/5 prostate cancer genes |
AU2003228811A1 (en) * | 2002-05-01 | 2003-11-17 | Irm Llc | Methods for discovering tumor biomarkers and diagnosing tumors |
US7919084B2 (en) * | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
US7157235B2 (en) * | 2002-06-17 | 2007-01-02 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
WO2004063355A2 (en) * | 2003-01-10 | 2004-07-29 | Protein Design Labs, Inc. | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer |
-
2008
- 2008-10-22 JP JP2010529197A patent/JP5272011B2/ja active Active
- 2008-10-22 WO PCT/AU2008/001554 patent/WO2009052557A1/en active Application Filing
- 2008-10-22 US US12/734,232 patent/US20110039284A1/en not_active Abandoned
- 2008-10-22 CA CA2701945A patent/CA2701945A1/en not_active Abandoned
- 2008-10-22 EP EP08842854.5A patent/EP2208072B1/en active Active
- 2008-10-22 CN CN200880113426.0A patent/CN101861522B/zh active Active
- 2008-10-22 ES ES08842854.5T patent/ES2543985T3/es active Active
-
2010
- 2010-09-06 HK HK10108448.9A patent/HK1142128A1/xx unknown
-
2013
- 2013-05-10 JP JP2013099935A patent/JP5734342B2/ja active Active
-
2015
- 2015-07-23 US US14/807,430 patent/US20160018401A1/en not_active Abandoned
-
2019
- 2019-09-10 US US16/565,542 patent/US20200003780A1/en not_active Abandoned
-
2022
- 2022-03-29 US US17/706,905 patent/US20230059466A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP5734342B2 (ja) | 2015-06-17 |
CN101861522B (zh) | 2014-05-14 |
JP2013174614A (ja) | 2013-09-05 |
WO2009052557A1 (en) | 2009-04-30 |
EP2208072A1 (en) | 2010-07-21 |
US20110039284A1 (en) | 2011-02-17 |
JP2011501136A (ja) | 2011-01-06 |
CN101861522A (zh) | 2010-10-13 |
EP2208072A4 (en) | 2011-01-26 |
CA2701945A1 (en) | 2009-04-30 |
JP5272011B2 (ja) | 2013-08-28 |
US20160018401A1 (en) | 2016-01-21 |
US20200003780A1 (en) | 2020-01-02 |
US20230059466A1 (en) | 2023-02-23 |
EP2208072B1 (en) | 2015-07-01 |
ES2543985T3 (es) | 2015-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1142128A1 (en) | Methods of prognosis | |
GB0706709D0 (en) | Methods | |
ZA201001878B (en) | Improved detection of mage-a-expression | |
GB0711697D0 (en) | Method of manufacture | |
HK1132673A1 (en) | Novel methods | |
AP2008004406A0 (en) | Methods of managing timberland | |
EP2234642A4 (en) | METHOD FOR INCREASING AN IMMUNOLOGICAL EFFECT | |
ZA200906490B (en) | New methods | |
GB0705854D0 (en) | Methods of construction | |
GB0718160D0 (en) | Methods | |
AP2784A (en) | Methods of managing timberland | |
EP2342355A4 (en) | METHODS OF USING BIOMARKERS | |
GB0701599D0 (en) | Method of detection | |
ZA200900636B (en) | Method of prognosis | |
EP2161998A4 (en) | NOVEL PROCEDURE | |
EP2205524A4 (en) | METHODS OF MANUFACTURING CLUSTER BORON | |
GB0715502D0 (en) | Methods | |
GB0714842D0 (en) | Methods | |
GB0707735D0 (en) | Methods | |
TWI348657B (en) | Determination method of edge direction | |
GB0711140D0 (en) | New methods | |
GB201114396D0 (en) | Location of basesation | |
GB0719252D0 (en) | Methods | |
GB0713673D0 (en) | Methods | |
AU2007905761A0 (en) | Methods of prognosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHRG | Changes in the register |
Free format text: ADDITION OF INVENTOR: GR |